½ÃÀ庸°í¼­
»óǰÄÚµå
1562205

À¯·´ÀÇ °ñ°üÀý¿° Ä¡·á ½ÃÀå ½ÃÀå ¿¹Ãø(-2030³â) : Áö¿ªº° ºÐ¼® - Ä¡·á À¯Çü, ÀûÀÀÁõ, ÃÖÁ¾»ç¿ëÀÚº°

Europe Osteoarthritis Therapy Market Forecast to 2030 - Regional Analysis - by Therapy Type, Disease Indication, and End User

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: The Insight Partners | ÆäÀÌÁö Á¤º¸: ¿µ¹® 108 Pages | ¹è¼Û¾È³» : Áï½Ã¹è¼Û

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

À¯·´ÀÇ °ñ°üÀý¿° Ä¡·á ½ÃÀåÀº 2022³â 49¾ï 7,151¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, 2030³â¿¡´Â 87¾ï 4,393¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2022³âºÎÅÍ 2030³â±îÁö ¿¬Æò±Õ 7.3%ÀÇ ¼ºÀå·üÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Àç»ýÀÇ·áÀÇ °¡¿ë¼ºÀÌ À¯·´ °ñ°üÀý¿° Ä¡·á ½ÃÀåÀ» ÁÖµµ

Àç»ýÀÇ·á´Â OA¸¦ Ä¡·áÇϱâ À§ÇÑ ±âÁ¸ Ä¡·á¹ýÀ» ´ëüÇÒ ¼ö ÀÖ´Â »õ·Î¿î ´ë¾ÈÀÌÀÚ Çõ½ÅÀÇ ÀáÀç·ÂÀ» °¡Áö°í ÀÖ½À´Ï´Ù. Àç»ýÀÇ·á´Â OA¸¦ Ä¡·áÇϱâ À§ÇØ ½ÅüÀÇ ¸é¿ªÃ¼°è¸¦ Ç¥ÀûÀ¸·Î ÇÏ´Â »ýü°øÇÐ, »ýüÀç·á, ¼¼Æ÷ Ä¡·áÁ¦¸¦ ÀÌ¿ëÇÕ´Ï´Ù. ¶ÇÇÑ, ÀÓ»ó ¿¬±¸ÀÚµéÀº ȯÀÚÀÇ(ÀÚ°¡) ¼¼Æ÷¸¦ »ç¿ëÇÏ¿© ȯÀÚÀÇ °üÀý ¿¬°ñÀ» °íÁ¤ÇÏ´Â ¹æ¹ýÀ» °³¹ßÇß½À´Ï´Ù. ¶Ç ´Ù¸¥ Àç»ý Ä¡·á ¿É¼ÇÀ¸·Î´Â "¸ÅÆ®¸¯½º À¯µµ ÀÚ°¡ ¿¬°ñ ¼¼Æ÷ À̽Ä(MACI)"ÀÌ Àִµ¥, MACI´Â ¿¬°ñÀÇ ÀÛÀº ºÎºÐÀ» º¹±¸ÇÏ°í ±Ã±ØÀûÀ¸·Î OA¸¦ ¿¹¹æÇϰųª Áö¿¬½Ãų ¼ö ÀÖ½À´Ï´Ù. ¿©·¯ Á¦Á¶¾÷üµéÀÌ Àç»ý Ä¡·á¿¡ ÃÊÁ¡À» ¸ÂÃá Á¦Ç°À» °³¹ßÇϰí ÀÖÀ¸¸ç, PRP Ä¡·á, Áٱ⼼Æ÷ Ä¡·á, È÷¾Ë·ç·Ð»ê ÁÖ»ç, ÇÁ·Ñ·ÎÅ×¶óÇÇ¿Í °°Àº ºñ¼ö¼úÀû Á¢±Ù¹ý¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁö¸é¼­ Àç»ý ÀÇÇÐÀÇ Ã¤ÅÃÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Ä¡·áÇÒ ¼ö ÀÖ½À´Ï´Ù. Àç»ý Ä¡·á ¿É¼ÇÀº ±Ã±ØÀûÀ¸·Î ÅëÁõÀ» ÁÙÀ̰í OA·Î °íÅë¹Þ´Â °³ÀÎÀÇ Àü¹ÝÀûÀÎ »îÀÇ ÁúÀ» Çâ»ó½ÃÄÑ °üÀý ±â´ÉÀ» °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. µû¶ó¼­ Àç»ýÀÇ·áÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¿¹Ãø ±â°£ µ¿¾È °ñ°üÀý¿° Ä¡·á ½ÃÀå¿¡¼­ »õ·Î¿î ºñÁî´Ï½º ±âȸ°¡ âÃâµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

À¯·´ÀÇ °ñ°üÀý¿° Ä¡·á ½ÃÀå °³¿ä

À¯·´ÀÇ °ñ°üÀý¿° Ä¡·á ½ÃÀåÀº µ¶ÀÏ, ¿µ±¹, ÇÁ¶û½º, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ ¹× ±âŸ À¯·´À¸·Î ±¸ºÐµË´Ï´Ù. Journal of Health Monitoring Àú³ÎÀÇ º¸°í¼­¿¡ µû¸£¸é, °ñ°üÀý¿°Àº µ¶ÀÏ¿¡¼­ °¡Àå ÈçÇÑ °üÀý ÁúȯÀ¸·Î, ÀÌ Áö¿ª¿¡¼­ °ñ°üÀý¿° Ä¡·áÀÇ ½Å¼ÓÇÑ Á¦Ç° ½ÂÀΰú ³ôÀº ¼öÁØÀÇ ÀÇ·á ÀÎÇÁ¶ó°¡ ½ÃÀå ¼ºÀåÀÇ °¡Àå À¯·ÂÇÑ ¿äÀÎÀ¸·Î ²ÅÈü´Ï´Ù. °ñ°üÀý¿°Àº »óÁö(¼Õ°¡¶ô, ¼Õ, ¾î±ú)¿¡ ¹ß»ýÇϱ⠶§¹®¿¡ °üÀýÀÇ ÅëÁõ°ú ±â´É ÀúÇÏ·Î ÀÎÇØ »îÀÇ ÁúÀÌ ÀúÇ쵃 °¡´É¼ºÀÌ ³ô½À´Ï´Ù. 2020³â ¹ßÇ¥µÈ ¼¼°èº¸°Ç±â±¸(WHO) º¸°í¼­¿¡ µû¸£¸é, µ¶ÀÏ¿¡¼­ °ñ°üÀý¿°À¸·Î ÀÎÇÑ »ç¸ÁÀÚ ¼ö´Â Àüü »ç¸ÁÀÚ ¼öÀÇ 0.05%¸¦ Â÷ÁöÇϸç, 2020³â µ¶ÀÏ¿¡¼­ °ñ°üÀý¿°À¸·Î ÀÎÇÑ »ç¸ÁÀÚ ¼ö´Â Àüü »ç¸ÁÀÚ ¼öÀÇ 0.05%¸¦ Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ½ÅÁ¦Ç° Ãâ½Ã´Â ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â 5¿ù, ±Û·ç³ÙÅ»Àº ÇöÀç ÀÓ»ó 3»ó °³¹ß ÁßÀÎ ºñ¿ÀÇÇ¿ÀÀÌµå °è¿­ÀÇ ÀÓ»ó½ÃÇè¿ë ¾à¹° '·¹Áö´ÏÆä¶óÅå½Å(RTX)ÀÌ ¹Ì±¹ ½ÄǰÀǾ౹(USFDA)À¸·ÎºÎÅÍ ¹«¸­ °üÀý OA Ä¡·áÁ¦·Î ½ÂÀÎ¹Þ¾Ò´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. ·¹½Ã´ÏÆä¶óÅå½ÅÀº Àå±âÀûÀÎ ÅëÁõ ¿ÏÈ­ ¹× °üÀý ±â´É °³¼±À» °¡Á®¿Í ¿ÀÇÇ¿ÀÀ̵带 »ç¿ëÇÏÁö ¾Ê´Â ÀÇ¹Ì ÀÖ´Â Ä¡·á ¿É¼ÇÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.

À¯·´ °ñ°üÀý¿° Ä¡·á ½ÃÀå ¸ÅÃâ ¹× 2030³â±îÁöÀÇ ¿¹Ãø(¹é¸¸ ´Þ·¯)

À¯·´ÀÇ °ñ°üÀý¿° Ä¡·á ½ÃÀå ¼¼ºÐÈ­

À¯·´ÀÇ °ñ°üÀý¿° Ä¡·á ½ÃÀåÀº Ä¡·á À¯Çü, ÀûÀÀÁõ, ÃÖÁ¾»ç¿ëÀÚ, ±¹°¡º°·Î ºÐ·ùµË´Ï´Ù.

Ä¡·á À¯Çüº°·Î À¯·´ °ñ°üÀý¿° Ä¡·á ½ÃÀåÀº °æÇÇÀû Àü±â½Å°æÀÚ±Ø(TENS), ÀÛ¾÷Ä¡·á, ¹°¸®Ä¡·á, Ç÷¼ÒÆÇdzºÎÇ÷Àå(PRP) Ä¡·á ¹× °£ÁúÇ÷°ü ºÐȹ, ÇÁ·Ñ·ÎÅ×¶óÇÇ, ±âŸ·Î ºÐ·ùµË´Ï´Ù. ¹°¸®Ä¡·á ºÐ¾ß°¡ 2022³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

ÀûÀÀÁõº°·Î À¯·´ °ñ°üÀý¿° Ä¡·á ½ÃÀåÀº ¹«¸­ °ñ°üÀý¿°, ôÃß °ñ°üÀý¿°, Á·ºÎ °ñ°üÀý¿°, ¾î±ú °ñ°üÀý¿°, ¼Õ¸ñ °ñ°üÀý¿°, ±âŸ·Î ³ª´¹´Ï´Ù. ¹«¸­ °ñ°üÀý¿° ºÎ¹®Àº 2022³â À¯·´ °ñ°üÀý¿° Ä¡·á ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

ÃÖÁ¾»ç¿ëÀÚº°·Î À¯·´ °ñ°üÀý¿° Ä¡·á ½ÃÀåÀº º´¿ø ¹× Ŭ¸®´Ð, Àü¹® Ŭ¸®´Ð, ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ, ÀçÅà ġ·á ¹× ±âŸ·Î ºÐ·ùµÇ¸ç, 2022³â À¯·´ °ñ°üÀý¿° Ä¡·á ½ÃÀåÀº ÀçÅà ġ·á ºÐ¾ß°¡ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.

±¹°¡º°·Î´Â À¯·´ °ñ°üÀý¿° Ä¡·á ½ÃÀåÀº ¿µ±¹, µ¶ÀÏ, ÇÁ¶û½º, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ, ±âŸ À¯·´À¸·Î ±¸ºÐµÇ¸ç, 2022³â À¯·´ °ñ°üÀý¿° Ä¡·á ½ÃÀå Á¡À¯À²Àº µ¶ÀÏÀÌ µ¶½ÄÇß½À´Ï´Ù.

Zimmer Biomet Holdings Inc, DePuy Synthes Inc, Bioventus Inc, Omron Healthcare Inc, Exactech Inc, Medi GmbH & Co KG´Â À¯·´ °ñ°üÀý¿° Ä¡·á ½ÃÀå¿¡¼­ Ȱµ¿ÇÏ´Â ÁÖ¿ä ±â¾÷ Áß ÀϺÎÀÔ´Ï´Ù. ÁÖ¿ä ±â¾÷ Áß ÀϺÎÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼Ò°³

Á¦2Àå ÁÖ¿ä ¿ä¾à

  • ÁÖ¿ä ÀλçÀÌÆ®

Á¦3Àå Á¶»ç ¹æ¹ý

  • Á¶»ç ¹üÀ§
  • 2Â÷ Á¶»ç
  • 1Â÷ Á¶»ç

Á¦4Àå °ñ°üÀý¿° Ä¡·á ½ÃÀå »óȲ

  • ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®
    • ÀÓ»ó½ÃÇè ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®

Á¦5Àå À¯·´ÀÇ °ñ°üÀý¿° Ä¡·á ½ÃÀå : ÁÖ¿ä ½ÃÀå ¿ªÇÐ

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • °ñ°üÀý¿° À¯º´·ü »ó½Â
    • Çõ½ÅÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ÀÇÇÑ ¾à¹° ÀÇÁ¸ °æ°¨
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • Á¦Ç° ȸ¼ö
  • ½ÃÀå ±âȸ
    • Àç»ýÀÇ·á ÀÌ¿ë °¡´É¼º
  • ÇâÈÄ µ¿Çâ
    • ´õ È¿°úÀûÀÎ Ä¡·á ¿É¼Ç
  • ¼ºÀå ÃËÁø¿äÀΰú ¾ïÁ¦¿äÀÎÀÇ ¿µÇâ

Á¦6Àå °ñ°üÀý¿° Ä¡·á ½ÃÀå : À¯·´ ½ÃÀå ºÐ¼®

    • °ñ°üÀý¿° Ä¡·á ½ÃÀå ¸ÅÃâ, 2020-2030³â

Á¦7Àå À¯·´ÀÇ °ñ°üÀý¿° Ä¡·á ½ÃÀå ºÐ¼® : Ä¡·á À¯Çüº°

  • °æÇÇÀû Àü±â ½Å°æÀÚ±Ø ¿ä¹ý(TENS)
  • ÀÛ¾÷Ä¡·á
  • ¹°¸®Ä¡·á
  • Ç÷¼ÒÆÇdzºÎÇ÷Àå ¿ä¹ý°ú ±âÁú Ç÷°ü ºÐȹ ¿ä¹ý
  • Áõ½ÄÄ¡·á
  • ±âŸ

Á¦8Àå À¯·´ÀÇ °ñ°üÀý¿° Ä¡·á ½ÃÀå ºÐ¼® : ÀûÀÀ Áúȯº°

  • ¹«¸­ °ñ°üÀý¿°
  • ôÃß °ñ°üÀý¿°
  • ¹ß ¹× ¹ß¸ñ °ñ°üÀý¿°
  • ¾î±ú °ñ°üÀý¿°
  • ¼Õ °ñ°üÀý¿°
  • ±âŸ

Á¦9Àå À¯·´ÀÇ °ñ°üÀý¿° Ä¡·á ½ÃÀå ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚº°

  • º´¿ø ¹× Ŭ¸®´Ð
  • Àü¹® Ŭ¸®´Ð
  • ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ
  • ÀçÅÃÀÇ·á
  • ±âŸ

Á¦10Àå À¯·´ÀÇ °ñ°üÀý¿° Ä¡·á ½ÃÀå : ±¹°¡º° ºÐ¼®

  • À¯·´ ½ÃÀå °³¿ä
    • À¯·´
      • ¿µ±¹
      • µ¶ÀÏ
      • ÇÁ¶û½º
      • ÀÌÅ»¸®¾Æ
      • ½ºÆäÀÎ
      • ±âŸ À¯·´

Á¦11Àå ¾÷°è »óȲ

  • °ñ°üÀý¿° Ä¡·á ½ÃÀåÀÇ ¼ºÀå Àü·«
  • À¯±âÀû Àü°³
  • ¹«±âÀû Àü°³

Á¦12Àå ±â¾÷ °³¿ä

  • Zimmer Biomet Holdings Inc
  • DePuy Synthes Inc
  • Bioventus Inc
  • Omron Healthcare Inc
  • Exactech Inc
  • Medi GmbH & Co KG

Á¦13Àå ºÎ·Ï

ksm 24.10.10

The Europe osteoarthritis therapy market was valued at US$ 4,971.51 million in 2022 and is expected to reach US$ 8,743.93 million by 2030; it is estimated to register a CAGR of 7.3% from 2022 to 2030 .

Availability of Regenerative Medicine Drives Europe Osteoarthritis Therapy Market

Regenerative medicine is a new and potentially transformative alternative to traditional therapy options to treat OA. Regenerative medicine utilizes biomedical engineering, biomaterials, and cell therapies that target the body's immune system to treat OA. Also, clinical researchers have developed methods to fix the articular cartilage of patients using patients' (autologous) cells. Further, regenerative therapy options use "Matrix-Induced Autologous Chondrocyte Implantation (MACI)." MACI can repair small areas of cartilage, ultimately preventing or postponing OA. Also, several manufacturers are developing products focused on regenerative therapy. Rising inclination toward non-surgical approaches such as PRP therapy, stem cell therapy, hyaluronic acid injections, and prolotherapy would propel the adoption of regenerative medicine. Patients suffering from OA can be treated using non-pharmacological therapies. Regenerative therapy options can improve joint functions by ultimately reducing pain and enhancing the overall quality of life for individuals suffering from OA. Therefore, increasing adoption of regenerative medicine is expected to open new business opportunities in the osteoarthritis therapy market during the forecast period.

Europe Osteoarthritis Therapy Market Overview

Europe osteoarthritis therapy market is segmented as Germany, the UK, France, Italy, Spain, and the Rest of Europe. Fast product approvals in the region for osteoarthritis treatment drugs and advanced healthcare infrastructure are the most influential factors responsible for market growth. According to the Journal of Health Monitoring report, osteoarthritis is the most common joint disease in Germany. Joint pain and loss of function are likely to result in loss of quality of life as osteoarthritis is caused in the upper extremities (fingers, hands, and shoulders). Therefore, with the aging of Germany's population, osteoarthritis prevalence will continue to rise, resulting in a high burden on the healthcare system. According to the World Health Organization (WHO) report published in 2020, osteoarthritis deaths in Germany account for 0.05% of total deaths. Further, new product launches enhance the market growth. For instance, in May 2023, Grunenthal announced receiving approval for investigational non-opioid medicine "Resiniferatoxin (RTX)," currently undergoing Clinical Phase 3 development standing as a breakthrough therapy by the US Food and Drug Administration (USFDA) to treat knee OA. Resiniferatoxin can become a meaningful non-opioid treatment option, providing long-lasting pain relief and functional improvement of the affected joint.

Europe Osteoarthritis Therapy Market Revenue and Forecast to 2030 (US$ Million)

Europe Osteoarthritis Therapy Market Segmentation

The Europe osteoarthritis therapy market is categorized into therapy type, disease indications, end user, and country.

Based on therapy type, the Europe osteoarthritis therapy market is segmented into transcutaneous electrical nerve stimulation (TENS), occupational therapy, physical therapy, platelet-rich plasma (PRP) therapy & stromal vascular fraction, prolotherapy, and others. The physical therapy segment held the largest market share in 2022.

In terms of disease indications, the Europe osteoarthritis therapy market is segmented into knee osteoarthritis, spine osteoarthritis, foot and ankle osteoarthritis, shoulder osteoarthritis, hand osteoarthritis, and others. The knee osteoarthritis segment held the largest share of Europe osteoarthritis therapy market in 2022.

Based on end users, the Europe osteoarthritis therapy market is categorized into hospitals and clinics, specialty clinics, ambulatory surgical center, homecare, and others. The homecare segment held the largest share of Europe osteoarthritis therapy market in 2022.

By country, the Europe osteoarthritis therapy market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe osteoarthritis therapy market share in 2022.

Zimmer Biomet Holdings Inc, DePuy Synthes Inc, Bioventus Inc, Omron Healthcare Inc, Exactech Inc, and Medi GmbH & Co KG are some of the leading companies operating in the Europe osteoarthritis therapy market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Osteoarthritis Therapy Market Landscape

  • 4.1 Pipeline Analysis
    • 4.1.1 Clinical Trial Pipeline Analysis

5. Europe Osteoarthritis Therapy Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Rising Prevalence of Osteoarthritis
    • 5.1.2 Innovative Therapy Options Reducing Dependency on Medications
  • 5.2 Market Restraints
    • 5.2.1 Product Recall
  • 5.3 Market Opportunities
    • 5.3.1 Availability of Regenerative Medicine
  • 5.4 Future Trends
    • 5.4.1 More Effective Treatment Options
  • 5.5 Impact of Drivers and Restraints:

6. Osteoarthritis Therapy Market - Europe Market Analysis

  • 6.1 Overview
    • 6.1.1 Osteoarthritis Therapy Market Revenue (US$ Million), 2020-2030

7. Europe Osteoarthritis Therapy Market Analysis - by Therapy Type

  • 7.1 Overview
  • 7.2 Transcutaneous Electrical Nerve Stimulation (TENS)
    • 7.2.1 Overview
    • 7.2.2 Transcutaneous Electrical Nerve Stimulation (TENS): Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.3 Occupational Therapy
    • 7.3.1 Overview
    • 7.3.2 Occupational Therapy: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Physical Therapy
    • 7.4.1 Overview
    • 7.4.2 Physical Therapy: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5 Platelet-Rich Plasma Therapy and Stromal Vascular Fraction
    • 7.5.1 Overview
    • 7.5.2 Platelet-Rich Plasma Therapy and Stromal Vascular Fraction: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.6 Prolotherapy
    • 7.6.1 Overview
    • 7.6.2 Prolotherapy: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.7 Others
    • 7.7.1 Overview
    • 7.7.2 Others: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe Osteoarthritis Therapy Market Analysis - by Disease Indication

  • 8.1 Overview
  • 8.2 Knee Osteoarthritis
    • 8.2.1 Overview
    • 8.2.2 Knee Osteoarthritis: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.3 Spine Osteoarthritis
    • 8.3.1 Overview
    • 8.3.2 Spine Osteoarthritis: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Foot and Ankle Osteoarthritis
    • 8.4.1 Overview
    • 8.4.2 Foot and Ankle Osteoarthritis: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.5 Shoulder Osteoarthritis
    • 8.5.1 Overview
    • 8.5.2 Shoulder Osteoarthritis: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.6 Hand Osteoarthritis
    • 8.6.1 Overview
    • 8.6.2 Hand Osteoarthritis: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.7 Others
    • 8.7.1 Overview
    • 8.7.2 Others: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)

9. Europe Osteoarthritis Therapy Market Analysis - by End User

  • 9.1 Overview
  • 9.2 Hospitals and Clinics
    • 9.2.1 Overview
    • 9.2.2 Hospitals and Clinics: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.3 Specialty Clinics
    • 9.3.1 Overview
    • 9.3.2 Specialty Clinics: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.4 Ambulatory Surgical Centers
    • 9.4.1 Overview
    • 9.4.2 Ambulatory Surgical Centers: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.5 Homecare
    • 9.5.1 Overview
    • 9.5.2 Homecare: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.6 Others
    • 9.6.1 Overview
    • 9.6.2 Others: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)

10. Europe Osteoarthritis Therapy Market - Country Analysis

  • 10.1 Europe Market Overview
    • 10.1.1 Europe: Osteoarthritis Therapy Market - Revenue and Forecast Analysis - by Country
      • 10.1.1.1 United Kingdom: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.1.1 Overview
        • 10.1.1.1.2 United Kingdom: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.1.3 United Kingdom: Osteoarthritis Therapy Market Breakdown, by Therapy Type
        • 10.1.1.1.4 United Kingdom: Osteoarthritis Therapy Market Breakdown, by Disease Indication
        • 10.1.1.1.5 United Kingdom: Osteoarthritis Therapy Market Breakdown, by End User
      • 10.1.1.2 Germany: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.2.1 Overview
        • 10.1.1.2.2 Germany: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.2.3 Germany: Osteoarthritis Therapy Market Breakdown, by Therapy Type
        • 10.1.1.2.4 Germany: Osteoarthritis Therapy Market Breakdown, by Disease Indication
        • 10.1.1.2.5 Germany: Osteoarthritis Therapy Market Breakdown, by End User
      • 10.1.1.3 France: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.3.1 Overview
        • 10.1.1.3.2 France: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.3.3 France: Osteoarthritis Therapy Market Breakdown, by Therapy Type
        • 10.1.1.3.4 France: Osteoarthritis Therapy Market Breakdown, by Disease Indication
        • 10.1.1.3.5 France: Osteoarthritis Therapy Market Breakdown, by End User
      • 10.1.1.4 Italy: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.4.1 Overview
        • 10.1.1.4.2 Italy: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.4.3 Italy: Osteoarthritis Therapy Market Breakdown, by Therapy Type
        • 10.1.1.4.4 Italy: Osteoarthritis Therapy Market Breakdown, by Disease Indication
        • 10.1.1.4.5 Italy: Osteoarthritis Therapy Market Breakdown, by End User
      • 10.1.1.5 Spain: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.5.1 Overview
        • 10.1.1.5.2 Spain: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.5.3 Spain: Osteoarthritis Therapy Market Breakdown, by Therapy Type
        • 10.1.1.5.4 Spain: Osteoarthritis Therapy Market Breakdown, by Disease Indication
        • 10.1.1.5.5 Spain: Osteoarthritis Therapy Market Breakdown, by End User
      • 10.1.1.6 Rest of Europe: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.6.1 Overview
        • 10.1.1.6.2 Rest of Europe: Osteoarthritis Therapy Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.6.3 Rest of Europe: Osteoarthritis Therapy Market Breakdown, by Therapy Type
        • 10.1.1.6.4 Rest of Europe: Osteoarthritis Therapy Market Breakdown, by Disease Indication
        • 10.1.1.6.5 Rest of Europe: Osteoarthritis Therapy Market Breakdown, by End User

11. Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies in the osteoarthritis therapy market
  • 11.3 Organic Developments
    • 11.3.1 Overview
  • 11.1 Inorganic Developments
    • 11.1.1 Overview

12. Company Profiles

  • 12.1 Zimmer Biomet Holdings Inc
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 DePuy Synthes Inc
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Bioventus Inc
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Omron Healthcare Inc
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Exactech Inc
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Medi GmbH & Co KG
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments

13. Appendix

  • 13.1 About the Insight Partners
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦